Please assess the completion status of the following clinical trial:

Trial Title: Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with the diagnosis of facial acne vulgaris having comedones, papules, pustules (≤5), or nodules (≤2) or Investigator's static global assessment score ≤4~* Treatment naïve patients or patients who had not taken topical anti-acne medications in last 14 days, systemic antibiotics in last 30 days, oral retinoids in last 12 months~Exclusion Criteria:~* Very severe acne vulgaris (Investigator's static global assessment score \>4)~* Any skin disorder that might interfere with the diagnosis or evaluation of acne vulgaris~* Known hypersensitivity to retinoids and clindamycin~* Any uncontrolled systemic disease or any cosmetic or surgical procedures complementary to the treatment of acne in the preceding 15 days~* Patients who were on oral contraceptive pills in last 12 weeks~* Pregnant and nursing women

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Tazarotene group (Type: EXPERIMENTAL): This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
- Adapalene group (Type: ACTIVE_COMPARATOR): This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).